- Home
- BSM vs VKTX Comparison
BSM vs VKTX Comparison
Compare BSM & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSM
- VKTX
- Stock Information
- Founded
- BSM 1876
- VKTX 2012
- Country
- BSM United States
- VKTX United States
- Employees
- BSM N/A
- VKTX N/A
- Industry
- BSM Oil & Gas Production
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- BSM Energy
- VKTX Health Care
- Exchange
- BSM Nasdaq
- VKTX Nasdaq
- Market Cap
- BSM 3.1B
- VKTX 2.8B
- IPO Year
- BSM 2015
- VKTX 2015
- Fundamental
- Price
- BSM $13.54
- VKTX $27.85
- Analyst Decision
- BSM Hold
- VKTX Buy
- Analyst Count
- BSM 2
- VKTX 12
- Target Price
- BSM $15.00
- VKTX $84.00
- AVG Volume (30 Days)
- BSM 326.7K
- VKTX 4.4M
- Earning Date
- BSM 05-05-2025
- VKTX 04-23-2025
- Dividend Yield
- BSM 11.07%
- VKTX N/A
- EPS Growth
- BSM N/A
- VKTX N/A
- EPS
- BSM 0.92
- VKTX N/A
- Revenue
- BSM $380,727,000.00
- VKTX N/A
- Revenue This Year
- BSM $14.57
- VKTX N/A
- Revenue Next Year
- BSM $8.16
- VKTX N/A
- P/E Ratio
- BSM $14.73
- VKTX N/A
- Revenue Growth
- BSM N/A
- VKTX N/A
- 52 Week Low
- BSM $12.80
- VKTX $18.92
- 52 Week High
- BSM $16.48
- VKTX $81.81
- Technical
- Relative Strength Index (RSI)
- BSM 36.84
- VKTX 54.95
- Support Level
- BSM $14.01
- VKTX $26.73
- Resistance Level
- BSM $14.58
- VKTX $30.28
- Average True Range (ATR)
- BSM 0.27
- VKTX 1.66
- MACD
- BSM -0.06
- VKTX 0.37
- Stochastic Oscillator
- BSM 6.78
- VKTX 65.19
About BSM Black Stone Minerals L.P. Common units representing limited partner interests
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.